ISLET Act
- Bill Number
- S. 3105
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-11-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-05-12T11:03:32Z
AI-Generated Summary
Purpose
The ISLET Act aims to classify human cadaveric islets—clusters of insulin-producing cells harvested from deceased donors—for transplantation as regulated organs, rather than as drugs, biological products, or certain tissue-based items. This change is intended to simplify and support life-saving endocrine transplants, particularly for treating type 1 diabetes, by aligning their oversight with existing organ transplant rules.
Key Provisions
- Amendment to Organ Regulation: Updates Section 374(d)(2) of the Public Health Service Act to explicitly include "human cadaveric islets" alongside organs like the pancreas, subjecting them to organ transplantation oversight.
- Exclusions from Other Categories: Clarifies that human cadaveric islets do not qualify as:
- A "drug" under the Federal Food, Drug, and Cosmetic Act (products intended to diagnose, cure, or prevent disease).
- A "biological product" under the Public Health Service Act (virus, serum, toxin, or similar product for preventing or treating diseases in humans).
- "Human cells, tissues, or cellular or tissue-based products (HCT/Ps)" under FDA regulations (minimally manipulated human cells or tissues for transplantation).
- Regulatory Updates and Reporting:
- The Secretary of Health and Human Services (HHS) must revise relevant regulations under the Public Health Service Act and Federal Food, Drug, and Cosmetic Act within 1 year of enactment to implement the changes.
- HHS must submit a progress report to Congress within 6 months of enactment.
Significant Changes to Existing Law
- Shifts human cadaveric islets from potentially stricter FDA oversight as drugs, biologics, or HCT/Ps—which often require extensive clinical trials, manufacturing standards, and pre-market approval—to the less burdensome framework for organ transplants under the Public Health Service Act.
- This reclassification removes islets from categories that could impose drug-like safety and efficacy reviews, treating them instead like solid organs (e.g., kidneys or pancreases) that are allocated and transplanted via established networks without full FDA drug approval processes.
Potential Impacts
- On Citizens: Could improve access to islet cell transplants for patients with severe type 1 diabetes, potentially reducing reliance on insulin therapy and lowering treatment costs by streamlining approvals and distribution.
- On Government Agencies: Requires HHS and the FDA to revise multiple sets of regulations, increasing short-term administrative workload but enabling more efficient organ transplant operations long-term. Organ procurement organizations may see expanded roles in islet recovery and allocation.
- On International Relations: No direct impacts noted, though it may indirectly influence global standards for islet transplantation research and sharing of cadaveric tissues.
Main Stakeholders Affected
- Patients and Healthcare Providers: Individuals with type 1 diabetes and endocrinologists/transplant surgeons who could benefit from easier access to islet transplants.
- Organ Procurement and Transplant Networks: Groups like the United Network for Organ Sharing (UNOS) that manage organ allocation, potentially handling more islet cases.
- Government Entities: HHS and FDA, responsible for regulatory updates; Congress, receiving oversight reports.
- Medical and Research Institutions: Hospitals and research centers involved in islet isolation and transplantation, facing reduced regulatory hurdles.
Notable Legal, Constitutional, or Political Implications
- Legal: Establishes a clear statutory classification for cadaveric islets, reducing ambiguity in federal oversight and potentially limiting future legal challenges over their treatment as experimental therapies. It preserves FDA authority over non-transplant uses while carving out an exception for organ-like transplants.
- Constitutional: Aligns with Congress's authority under the Commerce Clause to regulate interstate medical practices and public health, without raising evident free speech, privacy, or due process concerns.
- Political: Supports innovation in regenerative medicine by easing barriers to transplant therapies, appealing to bipartisan interests in healthcare affordability and chronic disease management; however, it may spark debates over safety standards if transplants increase without prior drug-like scrutiny.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Budd, Ted [R-NC], Sen. Tuberville, Tommy [R-AL], Sen. McCormick, David [R-PA]
Recent Actions
- 2025-11-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-11-05: Introduced in Senate
Bill Versions
- Increase Support for Life-saving Endocrine Transplantation Act — issued 2025-11-05 — PDF (3 pages)